ArticleJournal for immunotherapy of cancer2024

Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity.

Tamer Basel Shabaneh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.